Versant’s independent streak

Why Versant is putting Tempest on the path to independence with a $70M series B

With a $70 million series B round, Tempest Therapeutics Inc. marks the first disclosed newco out of Versant Ventures’ Inception Sciences Inc. incubator to stray from the VC’s build-to-buy model.

Versant, F-Prime Capital and Quan Capital led the round, joined by Lilly Asia Ventures,

Read the full 431 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE